BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
BriaCell Therapeutics (NASDAQ: BCTX) has published research validating the mechanism of action of its Bria-OTS+™ platform, a personalized, off-the-shelf cellular immunotherapy for cancer treatment. The study, conducted in collaboration with the National Cancer Institute (NCI), appeared in the peer-reviewed journal JCI Insight.
The research demonstrates that semi-allogeneic dendritic-cell vaccines can enhance anti-tumor responses through partial HLA matching and planned mismatching. This mechanism enables effective tumor-antigen presentation while driving robust CD4⁺ helper responses, supporting the clinical results observed in BriaCell's Phase 1/2a study in metastatic breast cancer.
The findings validate BriaCell's approach to developing scalable cancer immunotherapies and provide insights into how Bria-OTS+ may address unmet medical needs in cancer treatment.BriaCell Therapeutics (NASDAQ: BCTX) ha pubblicato uno studio che convalida il meccanismo d'azione della sua piattaforma Bria-OTS+™, una terapia cellulare immunologica personalizzata e pronta all'uso per il trattamento del cancro. La ricerca, svolta in collaborazione con il National Cancer Institute (NCI), è stata pubblicata sulla rivista peer-reviewed JCI Insight.
Lo studio dimostra che i vaccini a cellule dendritiche semi-allogeniche possono potenziare le risposte anti-tumorali grazie a un parziale matching HLA e a uno scontro programmato di mismatch. Questo meccanismo permette una presentazione efficace degli antigeni tumorali e nel contempo favorisce robuste risposte dei linfociti CD4⁺ helper, supportando i risultati clinici osservati nello studio di fase 1/2a di BriaCell sul carcinoma mammario metastatico.
I risultati convalidano l'approccio di BriaCell allo sviluppo di immunoterapie oncologiche scalabili e offrono indicazioni su come Bria-OTS+ possa colmare bisogni medici ancora insoddisfatti nel trattamento del cancro.
BriaCell Therapeutics (NASDAQ: BCTX) ha publicado una investigación que valida el mecanismo de acción de su plataforma Bria-OTS+™, una inmunoterapia celular personalizada y lista para usar contra el cáncer. El estudio, realizado en colaboración con el National Cancer Institute (NCI), se publicó en la revista revisada por pares JCI Insight.
La investigación muestra que las vacunas de células dendríticas semialogénicas pueden mejorar las respuestas antitumorales mediante un emparejamiento HLA parcial y un desajuste planificado. Este mecanismo permite una presentación eficaz de antígenos tumorales y, al mismo tiempo, induce fuertes respuestas de ayuda de los CD4⁺, respaldando los resultados clínicos observados en el estudio de fase 1/2a de BriaCell en cáncer de mama metastásico.
Los hallazgos validan el enfoque de BriaCell para desarrollar inmunoterapias oncológicas escalables y aportan información sobre cómo Bria-OTS+ podría abordar necesidades médicas no cubiertas en el tratamiento del cáncer.
BriaCell Therapeutics (NASDAQ: BCTX)는 개인 맞춤형의 즉시 사용 가능한 암 세포치료제 플랫폼인 Bria-OTS+™의 작용 기전을 입증한 연구 결과를 발표했습니다. 본 연구는 National Cancer Institute (NCI)와의 협력으로 수행되어 동료 검토 저널 JCI Insight에 게재되었습니다.
연구는 반동종(세미-알로제닉) 수지상세포 백신이 부분적 HLA 일치와 계획된 불일치를 통해 항종양 반응을 증강할 수 있음을 보여줍니다. 이 메커니즘은 종양 항원의 효과적인 제시를 가능하게 하면서도 강력한 CD4⁺ 헬퍼 반응을 유도해, 전이성 유방암을 대상으로 한 BriaCell의 1/2a상 임상 결과를 뒷받침합니다.
이 결과는 확장 가능한 암 면역치료제 개발에 대한 BriaCell의 접근법을 검증하며, Bria-OTS+가 암 치료의 미충족 의료 수요를 해결하는 데 어떻게 기여할 수 있는지에 대한 통찰을 제공합니다.
BriaCell Therapeutics (NASDAQ: BCTX) a publié une étude validant le mécanisme d'action de sa plateforme Bria-OTS+™, une immunothérapie cellulaire personnalisée et prête à l'emploi pour le traitement du cancer. L'étude, réalisée en collaboration avec le National Cancer Institute (NCI), est parue dans la revue évaluée par les pairs JCI Insight.
Les recherches démontrent que les vaccins à cellules dendritiques semi-allogéniques peuvent renforcer les réponses anti-tumorales grâce à un appariement partiel des HLA et à des mismatches planifiés. Ce mécanisme permet une présentation efficace des antigènes tumoraux tout en déclenchant de robustes réponses des cellules CD4⁺ auxiliaires, soutenant ainsi les résultats cliniques observés dans l'étude de phase 1/2a de BriaCell sur le cancer du sein métastatique.
Ces conclusions valident l'approche de BriaCell pour développer des immunothérapies oncologiques évolutives et apportent des éclairages sur la manière dont Bria-OTS+ pourrait répondre à des besoins médicaux non satisfaits en oncologie.
BriaCell Therapeutics (NASDAQ: BCTX) hat eine Studie veröffentlicht, die den Wirkmechanismus seiner Plattform Bria-OTS+™ bestätigt – einer personalisierten, sofort verfügbaren zellulären Immuntherapie gegen Krebs. Die Untersuchung erfolgte in Zusammenarbeit mit dem National Cancer Institute (NCI) und wurde in der peer-reviewed Fachzeitschrift JCI Insight publiziert.
Die Forschung zeigt, dass semi-allogene dendritische Zellimpfstoffe antitumorale Reaktionen durch partielles HLA-Matching und geplante Mismatches verstärken können. Dieser Mechanismus ermöglicht eine effektive Präsentation von Tumorantigenen bei gleichzeitiger Auslösung starker CD4⁺ Helferzellantworten und unterstützt die klinischen Ergebnisse der Phase-1/2a-Studie von BriaCell bei metastasiertem Brustkrebs.
Die Befunde bestätigen BriaCells Ansatz zur Entwicklung skalierbarer Krebsimmuntherapien und liefern Hinweise darauf, wie Bria-OTS+ ungedeckte medizinische Bedürfnisse in der Krebstherapie adressieren könnte.
- Validation of Bria-OTS+ mechanism of action by prestigious NCI collaboration
- Publication in highly-rated peer-reviewed journal JCI Insight
- Findings support positive clinical results from Phase 1/2a breast cancer study
- Technology demonstrates potential for scalable cancer treatment development
- None.
Insights
BriaCell's mechanism of action for Bria-OTS+ validated through NCI collaboration, strengthening scientific credibility for its personalized cancer immunotherapy platform.
The publication in JCI Insight represents a significant scientific milestone for BriaCell's Bria-OTS+ platform. Collaboration with the National Cancer Institute adds substantial credibility to the company's immunotherapy approach. The research validates that BriaCell's semi-allogeneic platform works through a dual mechanism: partial HLA matching enables tumor-antigen presentation while planned HLA mismatching drives robust CD4+ helper T-cell responses.
The scientific findings confirm that semi-allogeneic dendritic-cell vaccines can recruit alloreactive CD4+ T-cell help through mismatched MHC class II molecules, strengthening CD8+ T-cell responses against tumors. This molecular validation provides the scientific rationale behind the company's clinical results in metastatic breast cancer, where they previously reported encouraging outcomes.
For biotech investors, mechanistic validation from a prestigious institution like the NCI significantly de-risks the science behind BriaCell's platform. The publication in a high-impact journal provides third-party validation that their unique approach to personalized off-the-shelf cancer immunotherapy has sound scientific principles. This strengthens BriaCell's competitive position in the cellular immunotherapy landscape, particularly in addressing solid tumors like breast cancer where immunotherapy has historically shown limited efficacy.
- Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platform
- Bria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic cellular immunotherapy may address urgent unmet medical needs for patients with cancer
- This study was conducted in collaboration with the NCI
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the publication of the mechanism of action of its next generation personalized off-the-shelf immunotherapy. This research conducted in collaboration with the National Cancer Institute (NCI), the US federal government’s principal agency for cancer research and training, has been published at JCI Insight, a highly rated peer-reviewed journal dedicated to advancing biomedical research from preclinical discovery through to clinical development.
Publication Title: Enhancing dendritic cell cancer vaccine by allogeneic MHC class II expression and Treg depletion (our reference 189024-INS-RG-RV-4)
“These findings help us better understand the anti-tumor effects of Bria-OTS+ in cancer patients,” stated Jay A. Berzofsky, MD, PhD, Senior Investigator of NCI and coauthor of the publication. “The study demonstrated that semi-allogeneic dendritic-cell vaccines recruit alloreactive CD4⁺ T-cell help through mismatched MHC class II molecules, which in turn strengthens antigen-specific CD8⁺ T-cell responses against tumors.”
“This publication validates the core design principle behind Bria-OTS+: partial HLA matching enables effective tumor-antigen presentation, while planned HLA mismatching drives robust CD4⁺ helper responses,” noted Miguel Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer. “These findings are directly aligned with BriaCell’s pipeline of allogeneic immunotherapies, reinforcing our strategy to deliver powerful and scalable treatments for cancer patients.”
“These data are consistent with the encouraging clinical results we recently reported in our Phase 1/2a study in metastatic breast cancer and provide important insights into the mechanism of action of our cellular immunotherapy platform technology,” added Dr. William V. Williams, BriaCell’s President and CEO.
For the copy of the publication, please visit: https://briacell.com/scientific-publications/.
About Bria-OTS
Bria-OTS is a next generation, off-the-shelf personalized immunotherapy based on BriaCell’s lead candidate Bria-IMT currently being evaluated in a Phase 1/2a study (ClinicalTrials.gov identifier: NCT06471673) in patients with metastatic recurrent breast cancer. The trial includes both monotherapy dose escalation and check point inhibition combination dose expansion cohorts. The Company recently progressed into the dose expansion phase.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include statements regarding Bria-OTS+’s potential to address urgent unmet medical needs for patients with cancer; and BriaCell delivering powerful and scalable treatments for cancer patients. These statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
FAQ
What is the mechanism of action of BriaCell's (BCTX) Bria-OTS+ immunotherapy?
Who validated BriaCell's Bria-OTS+ cancer treatment platform?
What type of cancer is BCTX's Bria-OTS+ being tested for?
What makes BriaCell's (BCTX) cancer treatment unique?
